Top 10 Holdings of Our Ultimate Stock-Pickers' Index
We examine the biggest contributors to--and detractors from--the performance of the index during the past year.
Source: morningstar.com
Page 2 - Corus Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Corus Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Corus Pharma Today - Breaking & Trending Today
Gilead Sciences, Inc. (NASDAQ:GILD) - Recap: Gilead Sciences Q1 Earnings
52-week low: $56.56 Company Description Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell...
Source: benzinga.com